Ron receptor kinase (MST1R) is important in promoting epithelial tumorigenesis, but the potential contributions of its specific expression in stromal cells have not been examined. Herein 
Introduction
Coordinated signaling between different cell types of the stroma is required for the development and maintenance of an adult prostate secretory epithelium. The stroma also supports prostate tumor initiation and progression (1, 2) . Inflammatory infiltrates are major cellular components of tumor stroma and include adaptive and innate immune cell types (3, 4) . Tumorassociated immune cells support tumor growth by producing an immunosuppressive microenvironment capable of blocking productive antitumor immunity. Tumor-associated macrophages (TAM) play pivotal roles in tumor progression and can promote or inhibit tumor growth depending on their activation state (5, 6) .
The Ron receptor tyrosine kinase is expressed on several tissue-resident macrophage populations (7) (8) (9) (10) (11) . Ron activation in peritoneal macrophages suppresses inflammation and promotes alternative macrophage activation (12, 13) . Following lipopolysaccharide (LPS) stimulation in macrophages, Ron activation inhibits the expression of inducible nitric oxide synthase (iNOS) while promoting expression of arginase-1, an enzyme that competes with iNOS (14, 15) . iNOS-mediated nitric oxide production is cytotoxic and tumor suppressive, whereas products of arginase-1 promote tissue repair and tumorigenesis (16) .
Studies from our laboratory have shown Ron to be a negative regulator of inflammation in lung injury and bacterial peritonitis models (17, 18) . Using mice with myeloid cell-specific Ron deletion, macrophages were identified as the major cell type regulating inflammatory responses in lung and liver injury models (19, 20) . Ron signaling in peritoneal macrophages increases the phosphorylation of STAT3, suggesting an interaction between these two pathways (17, 21) . Moreover, STAT3 À/À mice show similar phenotypic responses as that of Ron-deficient mice (22) . Phosphorylation of STAT3 in TAMs is important for attenuating antitumor immunity by suppressing macrophage-mediated antigen presentation to cytotoxic CD8 þ T lymphocytes (23, 24) . Given that Ron regulates macrophage activation and inflammation, Ron signaling in TAMs may be important for maintenance of an immunosuppressive microenvironment. Ron is overexpressed in more than 90% of human prostate cancers (25) (26) (27) . Ron activation in tumor cells elicits a range of cellular responses including growth, differentiation, migration, and survival through various signaling pathways (27, 28) . Gainand loss-of-function studies in tumor epithelial cells, including human prostate cells, have shown that Ron expression is important for promoting tumor growth in vivo (29) (30) (31) (32) . Moreover, data from our laboratory have shown that mice containing a germline deletion of the Ron tyrosine kinase-signaling domain exhibit significant reduction in tumor mass when bred to mice predisposed to develop prostate cancer (32) . While numerous studies have outlined the importance of epithelialexpressed Ron in supporting tumorigenesis, the importance of Ron expression in the tumor stroma has not been extensively investigated. Although a recently published study outlined the importance of Ron expression in the tumor microenvironment, the Ron-expressing stromal cell lineage that supported tumor growth was not identified (13) .
This study identifies Ron expression in the stroma, particularly in TAMs, to be a critical factor that supports tumor growth through the regulation of apoptosis in tumor epithelial cells. In addition, we show that Ron expression in TAMs suppresses tumor immune surveillance through CD8 þ T-cell regulation and that Ron-expressing TAMs have increased activation of STAT3. Our findings indicate that in addition to the well-established tumor-cell autonomous role, Ron plays a novel role in TAMs by promoting tumor cell survival through cytotoxic CD8 þ T-cell regulation.
Materials and Methods
), homozygous Ron-floxed mice (TK f/f ), and LysMcre (TK f/f LysMcre þ ) mice were generated and maintained in a C57BL/6 background as described (20, 33) . All experiments used 8-to 12-week-old male mice. For bone marrow transplantation, donor bone marrow cells from TK þ/þ and TK À/À mice were injected into the tail vein of irradiated mice (Supplementary Methods). All mice were maintained under specific pathogen-free conditions and were treated in accordance with protocols approved by the Institutional Animal Care and Use Committee of the University of Cincinnati (Cincinnati, OH).
Cell lines and orthotopic injections
Murine TRAMP-C2Re3 cells were obtained from Dr. Zhongyun Dong (University of Cincinnati) and grown as previously described (34) . The cells are of murine origin and were tested through growth in syngeneic mice; no further validation was conducted. Cells (2.5 Â 10 5 ) were injected into the ventrolateral prostates of mice and harvested after 30 days (26).
T-cell depletion
Mice were subcutaneously injected with 5 Â 10 5 TRAMPC2Re3 cells. To deplete T-cell subsets, mice were injected on days 1, 7, 14, 21, and 24 with 1 mg/mL of rat monoclonal antibody that depleted specific lymphocyte subsets: mAb-GK1.5 (anti-CD4, IgG2b); mAb-2.43 (anti-CD8, IgG2b); and Rat-IgG2b isotype control antibody (JK; Bio X Cell). Tumor volume was recorded biweekly and tumors were harvested on day 28.
Cell isolations
A single-cell suspension of normal or tumor-bearing prostate tissue was obtained by mechanical dissociation and enzymatic digestion. Enrichment for epithelial cells, fibroblasts, and immune cells was accomplished by differential centrifugation using standard procedures (Supplementary Methods). TAMs were enriched from the immune cell fraction by magnetic beads coated with mouse CD11b according to manufacturer's instructions (Miltenyi Biotech). The isolated cells were more than 95% pure.
Flow analysis
Immune infiltrates were treated with Fc anti-CD16/CD32 antibody and stained with antibodies that detect macrophages (anti-mCD11b), granulocytes (anti-mGr-1), and CD8 þ T cells (anti-mCD8a; eBiosciences). Epithelial cells were stained for Annexin V/propidium iodide (PI), as per manufacturer's instructions (BD Biosciences). Cells were analyzed using the fluorescence-activated cell sorting (FACS) Aria and FACS Diva software (BD Biosciences).
Luminex array
Plasma was analyzed using the Milliplex Map Mouse Cytokine/Chemokine Panel with Luminex Map detection as per manufacturer's instructions (Millipore, #MPXMCYTO-70).
Immunohistochemistry
Formalin-fixed paraffin-embedded sections were stained for F4/80 (eBiociences), CD-31 (Dako), and alpha smooth muscle actin (a-SMA; Sigma-Aldrich) using standard procedures.
Human tissue array and scoring
Immunohistochemistry for Ron was conducted on human prostate cancer tissue microarray specimens (IMH-303, Imgenex; TMA1202-4, Chemicon/Millipore; 75-4063, Zymed), using the Ron-a antibody (BD-Transduction Laboratories). The percentage of Ron-positive stromal cells was determined and staining intensity graded (0-3). The stromal staining index, a factor of the staining percentage and intensity, was obtained for each tissue section.
Quantitative real-time PCR and immunoblot analyses
Quantitative real-time PCR (qRT-PCR) was conducted using primer pairs listed in the Supplementary Methods as previously described (20) . Expression levels were normalized to b-glucuronidase and relative gene expression reported. Western blot analyses used the following antibodies: Ron-C20 (Santa Cruz Biotechnologies) STAT3 and pSTAT3-Y705 (Cell Signaling) and arginase-1 (BD Biosciences).
Statistical analysis
Data are expressed as mean AE SE. Statistical significance was determined by t tests for pairwise comparisons or ANOVA for comparison of multiple groups with Graph Pad Prism software. Significance was set at P < 0.05.
Results
Ron is expressed in stromal cells of normal and tumorbearing prostates and is critical for promoting prostate tumor growth
Ron mRNA expression was detected in primary cells isolated from the prostates of TK þ/þ mice including resident prostate macrophages, epithelial cells, and fibroblasts (Fig.  1A) . Ron expression in human stromal cells was examined by immunohistochemistry on a panel of human prostate tissues. As depicted in Fig. 1B , Ron was detected in the stromal cells of normal human prostates, benign prostate hyperplasia, and prostate adenocarcinoma samples at approximately similar levels. Interestingly, Ron expression in stromal cells did not parallel its expression in the prostate epithelium, which has been previously shown to increase with disease progression (26) . While the levels of stromal Ron are not altered with prostate tumor progression, the functional role of this receptor may be regulated by the availability/processing of its ligand, hepatocyte growth factor-like protein, whose expression has been reported to increase with tumor progression (36) (37) (38) (39) .
The role of Ron expression in the tumor microenvironment was assessed after orthotopic transplantation of TRAMP- hosts revealed similarities in tissue architecture (Fig. 1D ). These findings show that Ron expression in the prostate tumor microenvironment is a critical mediator of prostate tumor growth.
Comparison of the stromal compartment in TK , n ¼ 5; Ã , P < 0.05). Scale bar, 50 mm. B, representative images showing CD31 staining in microvessels and quantification of the microvessel density per tumor area ( Ã , P < 0.01). Scale bar, 100 mm. C, a-SMA-positive fibroblasts in the tumors and the average intensity of a-SMA expression per Â40 field ( Ã , P < 0.01). Scale bar, 50 mm.
The impact of stromal Ron on tumor vascularization was determined by microvessel staining, which showed a significant increase in microvessel density in tumors from TK þ/þ hosts compared with tumors in TK À/À mice (Fig.   2B ). Immunohistochemistry for tumor-associated myofibroblasts showed an increase in a-SMA staining in tumors from TK À/À prostates as compared with controls (Fig. 2C) . Taken together, our data show that Ron signaling in the host regulates key events linked with tumor malignancy including angiogenesis, a-SMA expression, and macrophage infiltration.
Lack of host Ron expression promotes prostate cancer cell apoptosis Given the significant difference in tumor size in TK shown). Blood nitrite levels were also increased in the sera from tumor-bearing TK À/À animals ( Fig. 4B) . Expression of interleukin (IL)-9, monokine induced by gamma interferon (MIG/ CXCL9), and IL-17 was significantly greater in tumor-bearing TK À/À sera, whereas macrophage colony-stimulating factor (M-CSF) was higher in TK þ/þ sera (Fig. 4C) . Intratumoral gene expression examined by qRT-PCR showed significant increases in MIG and TNF-a expression in tumors from TK À/À hosts as Fig. S3A ). Significant increases in the intratumoral expression of STAT1, CXCR3, IL-12b, and ICOS were observed in tumor cells from TK À/À hosts compared with controls, whereas CD80 and IL-27 levels did not change (Fig. 4D) Fig. 5A and B) . At baseline, no appreciable differences in the number of myeloid precursor cells were noted between genotypes ( Supplementary Fig. S4 ). Irradiation had no effect on the growth of TRAMP-C2Re3 cells (Fig. 5C ). However, tumor growth was significantly Fig. 2A and Supplementary Fig. S1 ). TAMs from TK f/f tumors (Fig. 6A) . To test the functional importance of Ron-expressing myeloid cells, prostate tumor weight was compared across genotypes. Growth of TRAMPC2Re3 cells was significantly reduced in TK f/f LysMcre þ animals compared with controls (Fig. 6B) . Flow analysis for Annexin V/PI on tumors from TK f/f LysMcre þ mice showed a significant increase in total apoptotic and dead cells compared with controls, signifying that lack of Ron in myeloid cells is sufficient to inhibit tumor growth through a mechanism that induces tumor-cell apoptosis (Fig. 6C) . Immunohistochemistry for macrophages on tumors from TK f/f and TK f/f LysMcre þ mice indicated a significant increase in macrophage numbers in TK f/f LysMcre þ tumors compared with controls, thus reaffirming studies, whereby Ron-deficient macrophages localize to the tumors in greater numbers (Fig. 6D) . Moreover, iNOS expression was increased in tumors from TK f/f LysMcre þ mice , and bone marrow transplantation mice. Tumor progression in both chimeras was delayed compared with TK hosts compared with the controls, although this number was not significant (Supplementary Fig. S6A and S6B ). To determine if macrophage-mediated education of CD4 þ and CD8 þ T cells was important for reduced tumor burden in TK À/À mice, mice were depleted of CD4
Myeloid-specific
þ , or both T-cell subsets by injection of cytotoxic monoclonal antibodies. To allow for accurate measurement of tumor growth, TRAMP-C2Re3 cells were injected subcutaneously and tumor growth was assessed biweekly. The efficiency with which T-cell subsets were depleted was determined by flow analysis (>99%) for T-cell subset markers on splenocytes obtained at the time of sacrifice (Supplementary Fig. S6C ). As shown in Fig. 7A , TRAMP-C2Re3 cells grew similarly in the TK þ/þ and TK À/À mice in the subcutaneous environment compared with the prostate microenvironment (Fig. 1C) , wherein a 3-fold increase in tumor growth was observed in the TK þ/þ mice as compared with TK À/À mice; however, TRAMP-C2Re3 cells implanted orthotopically grew approximately 2-fold faster than cells implanted subcutaneously, despite the reduced inoculum cell numbers (40) . Depletion of CD4 þ T cells had a limited effect on tumor growth in both genotypes, as tumor growth in TK þ/þ versus TK À/À mice was similar to that of isotype-treated controls ( Fig.   7A and B) . In contrast, depletion of CD8 þ T cells restored tumor growth in TK À/À animals to that of controls. Depletion (Fig. 7C and D) . Taken together, our results indicate that Ron expression in the tumor microenvironment, specifically in macrophages, aids in evasion of tumor immune surveillance by impacting CD8 þ Tcell function.
Discussion
Tumors are regulated by complex signaling networks involving interactions between malignant epithelial cells and the adjacent stroma. While many publications have reported the importance of tumor-stromal interactions for supporting tumor growth, further investigations are required for the identification of the stromal cellular mediators and their associated signaling networks that promote tumorigenesis. In this report, we provide compelling evidence supporting the novel role for the Ron receptor in regulating tumor growth by virtue of its signaling in host bone marrow-derived cells, particularly myeloid cells, of the tumor microenvironment.
Myeloid cells and bone marrow-derived precursors are recruited to tumors and promote tumor growth, neovascularization, and aid in antitumor immune suppression (3, 41) . Our Fig. S4 and ref. 33 ). These results suggest that Ron deficiency does not affect the number and development of the hematopoietic cell lineages, but instead improves localization of macrophages to tumors. Loss of Ron expression in the host environment also resulted in an increase in the expression of inflammatory cytokines including IL-9, MIG, IL-17, and TNF-a, which are known to promote macrophage infiltration and inhibit tumor growth through mechanisms that regulate phagocytic activity or support the activation of effector cells of the innate and adaptive immune responses. Alternatively, the increase in TK À/À TAMs in either host genotype may be due to the need to clear cellular debris. The underlying mechanism that leads to the increased localization of macrophages to tumors in the presence of TK À/À bone marrow-derived cells as well as the functional significances of increased macrophage numbers on tumor growth warrants further investigation. In addition to the increased influx of Ron-deficient macrophages to tumors, our data show that a conditional loss of Ron in myeloid cells is sufficient to inhibit tumor growth in vivo. These studies are analogous to several previous studies, which showed decreased tumor growth in mice harboring myeloidspecific deletions of inhibitor of IkB kinase-b (IKK-b; ref. 42 ), STAT3 (43, 44) , hypoxia-inducible factor-1a (HIF-1a; ref. 45) , and HIF-2a (46) . A previous study on IKK-b has shown that deletion of this gene in either epithelial cells (enterocytes) or myeloid cells reduces colitis-associated cancer. In this study, enterocyte IKK-b expression promoted tumorigenesis by suppressing apoptosis, whereas myeloid expression enhanced tumor growth by controlling the production of inflammatory mediators, showing distinct roles for the protein in different cell types (42) . The cell-type specific regulation of tumor growth by Ron is similar to that observed for IKK-b. Published studies have shown that loss of Ron in prostate cancer epithelial cells leads to a reduction in tumor growth by promoting epithelial cell apoptosis and limiting tumor vascularization (26, 32) . In myeloid cells, Ron loss leads to increased tumor cell apoptosis associated with alterations in the inflammatory microenvironment and is independent of an effect on blood vessel formation. Of note, our data using bone marrow transplantation in chimeric mice suggested that in addition to hematopoietic cells, other nonhematopoietic Ron-expressing stromal cell types contribute to tumor progression. These data reinforce the notion of multiple cell-type specific roles for Ron in promoting tumor growth.
Previous studies from our laboratory in peritoneal macrophages have shown that Ron activation enhances macrophage STAT3 phosphorylation, whereas macrophages from TK À/À mice exhibit decreased STAT3 activation (17) . Consistent with this data, our current study shows that Ron loss is associated with lower STAT3 activity in TAMs. STAT3 signaling in macrophages attenuates antitumor immunity in a variety of in vivo tumor models (23, 47) . Similar to the studies in this report, disruption of STAT3 in myeloid cells through the use of LysMcre mice enhanced the ability of macrophages to stimulate CD8
þ T-cell activity in response to tumor antigens (23) .
Ron signaling may also regulate T-cell activity through the induction of T-cell anergy by downregulating the expression of costimulatory molecules or regulating cytokine/chemokine production. A significant induction in costimulatory molecules CXCR3 and ICOS as well as an induction of IL-9, iNOS, and MIG were observed in tumors taken from TK À/À compared with wild-type hosts, suggesting multiple components downstream of Ron that may regulate T-cell activity. While further studies are needed to determine the mechanism(s) by which myeloidspecific Ron signaling regulates tumor growth, our experiments with depletion of CD8 þ T cells in TK f/f LysMcre þ mice suggest that Ron loss in myeloid cells leads to enhanced tumor cell death through a mechanism that may depend upon STAT3 signaling and the activation of the immune response. Moreover, given the lack of current technologies to effectively target transcription factors such as STAT3, targeting Ron may serve as an important surrogate to activate the immune response for cancer therapy. In addition to alterations in the immune response, Ron signaling has been shown to regulate key metabolites that support an immunosuppressive tumor microenvironment. Ron activation in macrophages results in the inhibition of iNOS and increased arginase-1 expression (15, 33) . iNOS expression in tumor tissues has been shown to be either proor antitumorigenic, depending on the level of expression and the duration of NO (48) . Consistent with published observations, Ron loss in the tumor microenvironment increased local expression of iNOS. This increase in iNOS expression may be partly attributed to the expression of Ron in myeloid cells, as tumors from TK f/f LysMcre þ mice also displayed increases in iNOS levels compared with controls. Taken together, our data suggest that Ron expression in myeloid cells is important for regulating the fine balance of iNOS expression, which may skew the microenvironment toward a tumor-promoting state. Conversely, expression of arginase-1 has been reported to protect tissue from damage. Consistently, our data show that Ron-deficient TAMs exhibited significant decreases in arginase-1 levels. The downregulation of arginase-1 in Ron-deficient TAMs may be significant, as arginase-1 and arginine have been shown to be important in regulating a variety of T-cell activities including proliferation, differentiation, and activation (49, 50) . In summary, our data suggest a new role for Ron in regulating tumor intrinsic and extrinsic circuits within the tumor microenvironment. In light of immune impairment in individuals with cancer, short-term blockade of Ron in a controlled manner, such as the infusion of Ron-inhibited macrophages, may reverse the immunosuppressive microenvironment and activate antitumor immune responses. Further research in dissecting bidirectional signaling and the context-dependent role of Ron in cancer may provide a novel therapeutic strategy to improve the efficacy of cancer therapy.
